Morris, Valerie (2012) Second Generation Tyrosine Kinase Inhibitor Effective In First Line CML Therapy. Science Spotlight, 2 (10).
Preview |
Text
Second Generation Tyrosine Kinase Inhibitor Effective In First Line CML Therapy.pdf - Published Version Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (361kB) | Preview |
Article URL: http://www.bloodjournal.org/content/120/19/3898
| Item Type: | Article or Abstract |
|---|---|
| Additional Information: | Radich JP, Kopecky KJ, Appelbaum FR, Kamel-Reid S, Stock W, Malnassy G, Paietta E, Wadleigh M, Larson RA, Emanuel P, Tallman M, Lipton J, Turner AR, Druker BJ. 2012. A randomized trial of dasatinib 100 mg vs imatinib 400 mg in newly diagnosed chronic phase chromic myeloid leukemia. Blood. Epub ahead of print, doi: 10.1182/blood-2012-02-410688. |
| Collections: | Science Spotlight |
| Depositing User: | Users 60 not found. |
| Date Deposited: | 20 Mar 2015 21:53 |
| Last Modified: | 20 Mar 2015 21:53 |
| URI: | http://authors.fhcrc.org/id/eprint/896 |
Repository Administrators Only
 |
View Item |
